Vulvovaginal candidiasis: A review;La candidose vulvovaginale: revue

Journal de Mycologie Medicale

Volumn 20, Issue 2, 2010, Pages 108-115

  Amouri, I ^a   Abbes, S ^a   Sellami, H ^a   Makni, F ^a   Sellami, A ^a   Ayadi, A ^a  

^a UNIVERSITY OF SFAX   (Tunisia)

Author keywords

Diagnostic; Epidemiology; Pathogenesis; Treatment; Vulvovaginale candidiasis

Indexed keywords

AMPHOTERICIN B; BUTOCONAZOLE; CLOTRIMAZOLE; ECHINOCANDIN; ECONAZOLE; FENTICONAZOLE; FLUCONAZOLE; FLUCYTOSINE; ITRACONAZOLE; KETOCONAZOLE; MEDROXYPROGESTERONE; MICONAZOLE; NYSTATIN; SERTACONAZOLE; TERCONAZOLE; TIOCONAZOLE; VORICONAZOLE;

CANDIDA ALBICANS; FEMALE; FUNGAL COLONIZATION; FUNGAL VIRULENCE; FUNGUS GROWTH; HOST RESISTANCE; HUMAN; IMMUNOSURVEILLANCE; PATHOGENESIS; PREGNANCY; RECURRENT DISEASE; REVIEW; VAGINA CANDIDIASIS;

CANDIDA;

EID: 77953621896     PISSN: 11565233     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mycmed.2010.01.005     Document Type: Review

References (70)

1. Abbott J. Clinical and microscopic diagnosis of vaginal yeast infection: a prospective analysis. Ann Emerg Med 1995, 25:587-591.
2. Abu-Elteen K.H. Increased incidence of vulvovaginal candidiasis caused by Candida glabrata in Jordani. Jpn J Infect Dis 2001, 54:103-107.
3. Auler M.E., Morreira D., Rodrigues F.F., Abr Ao M.S., Margarido P.F., Matsumoto F.E., et al. Biofilm formation on intrauterine devices in patients with recurrent vulvovaginal candidiasis. Med Mycol 2010, 48:211-216.
4. Babula O., Lazdane G., Kroica J., Ledger W.J., Witkin S.S. Relation between recurrent vulvovaginal candidiasis, vaginal concentrations of mannose-binding lectin, and a mannose binding lectin gene polymorphism in Latvian women. Clin Infect Dis 2003, 37:733-737.
5. Barousse M.M., Steele C., Dunlap K., Espinosa T., Boikov D., Sobel J.D., et al. Growth inhibition of Candida albicans by human vaginal epithelial cells. J Infect Dis 2001, 184:1489-1493.
6. Bauters Tiene G.M., Dhont M.A., Temmerman Marleen I.L., Nelis H.J. Prevalence of vulvovaginal candidiasis and susceptibility to fluconazole in women. Am J Obstet Gynecol 2002, 187:596-602.
7. Black C.A., Eyers F.M., Russell A., Dunkley M.L., Clancy R.L., Beagley K.W. Acute neutropenia decreases inflammation associated with murine vaginal candidiasis but has no effect on the course of infection. Infect Immun 1998, 66:1273-1275.
8. Brown H.L., Fuller D.D., Jasper L.T., Davis T.E., Wright J.D. Clinical evaluation of affirm VPIII in the detection and identification of Trichomonas vaginalis Gardnerella vaginalis, and Candida species in vaginitis/vaginosis. Infect Dis Obstet Gynecol 2004, 12:17-21.
9. Calderon L., Williams R., Martinez M., Clemons K.V., Stevens D.A. Genetic susceptibility to vaginal candidiasis. Med Mycol 2003, 41:143-147.
10. Casadevall A., Pirofski L.A. A reappraisal of humoral immunity based on mechanisms of antibody-mediated protection against intracellular pathogens. Adv Immunol 2006, 91:1-44.
11. Casadevall A. Antibody immunity and invasive fungal infections. Infect Immun 1995, 63:4211-4218.
12. Cassone A., De Bernardis F., Santoni G. Anticandidal immunity and vaginitis: novel opportunities for immune intervention. Immun Infect 2007, 75:4675-4686.
13. CDC. Sexually transmitted diseases treatment Guidelines 2006. MMWR 2006;55:56-8.
14. Chaim W., Foxman B., Sobel J.D. Association of recurrent vaginal candidiasis and secretory ABO and Lewis phenotype. J Infect Dis 1997, 176:828-887.
15. Clemons K.V., Spearow J.L., Parmar R., Espiritu M., Stevens D.A. Genetic susceptibility of mice to Candida albicans vaginitis correlates with oestrogen sensitivity. Infect Immun 2004, 72:4878-4880.
16. Corselloa S., Spinillob A., Osnengoc G., Pennad C., Guaschinoe S., Beltramef A., et al. An epidemiologic survey of vuvovaginal candidiasis in Italy. Eur J Obstet Gynecol Reprod Biol 2003, 110:66-72.
17. Cutler J.E., Deepe G.S., Klein B.S. Advances in combating fungal diseases: vaccins on the threshold. Nat Rev Microbiol 2007, 5:13-28.
18. De Bernardis F., Liu H., O'Mahony R., La Valle R., Bartollino S., Sandini S., et al. Human domain antibodies against virulence traits of Candida albicans inhibit fungus adherence to vaginal epithelium and protect against experimental vaginal candidiasis. J Infect Dis 2007, 195:149-157.
19. De Carvalho R.J., Cunha C.M., Silva D.A., Sopelete M.C., Urzedo J.E., Moreira T.A., et al. IgA, IgE and IgG subclasses to Candida albicans in serum and vaginal fluid from patients with vulvovaginal candidiasis. Rev Assoc Med Bras 2003, 49:434-438.
20. De Leon E.M., Jacober S.J., Sobel J.D., Foxman B. Prevalence and risk factors for vaginal Candida colonization in women with type 1 and type 2 diabetes. BMC Infectious Dis 2002, 2:1-6.
21. Du C., Calderone R.A. Phagocytosis and killing assays for Candida species. Methods Mol Biol 2009, 499:17-26.
22. Falagas M.E., Betsi J.I., Athanasiou S. Probiotics for prevention of recurrent vulvovaginal candidiasis: a review. J Antimicrob Chemother 2006, 58:266-272.
23. Faye-Kette Y.H., Kouassi A.A., Sylla-Koko D.F., Kacou-N'-Douba A., Akoua-Koffi G., Acho Y.B., et al. Prevalence of 4 agents of sexually transmitted diseases in leukorrhea in Abidjan (Ivory Coast). Bull Soc Pathol Exot 1993, 86:245-247.
24. Fidel P.L., Barousse M., Espinosa T., Ficarra M., Sturtevant J., Martin D.H., et al. An intravaginal live candida challenge in humans leads to new hypotheses for the immunopthogenesis of vulvovaginal candidiasis. Infect Immun 2004, 72:2939-2946.
25. Fidel P.L., Luo W., Steele C., Chabain J., Baker M., Wormley F. Analysis of vaginal cell populations during experimental vaginal candidiasis. Infect Immun 1999, 67:3135-3140.
26. Fidel P.L. Immune regulation and its role in the pathogenesis of Candida vaginitis. Curr Infect Dis Rep 2003, 5:488-493.
27. Fleury F.J. Adult vaginitis. Clin Obstet Gynecol 1981, 24:407-438.
28. Fulurija A., Ashman R.B., Papadimitriou J.M. Neutrophil depletion increases susceptibility to systemic and vaginal candidiasis in mice, and reveals differences between brain and kidney in mechanisms of host resistance. Microbiology 1996, 142:3487-3496.
29. Geiger A.M., Foxman B. Risk factors for vulvovaginal candidiasis: a case-control study among university students. Epidemiology 1996, 7:182-187.
30. Giraldo P., Von Nowaskonski A., Gomes F.A.M., Linhares I., Neves N.A., Witkin S.S. Vaginal colonization by Candida in asymptomatic women with and without a history of recurrent vulvovaginal candidiasis. Obstet Gynecol 2000, 95:413-416.
31. Goswami D., Goswami R., Banerjee U., Dadhwal V., Miglani S., Abdul Lattif A., et al. Pattern of Candida species from patients with diabetes mellitus and vulvovaginal candidiasis and their response to single dose oral fluconazole therapy. J Inf 2006, 52:111-117.
32. Grigoriou O., Baka S., Makrakis E., Hassiakos D., Kapparos G., Kouskouni E. Prevalence of clinical vaginal candidiasis in a university hospital and possible risk factors. Eur J Obstet Gynecol Reprod Biol 2006, 126:121-125.
33. Gugnani H.C., Nzelibe F.K., Gini P.C., Chukudebelu W.O., Njoku-Obi A.N. Incidence of yeasts in pregnant and non-pregnant women in Nigeria. Mycoses 1989, 32:131-135.
34. Hurley R., De Louvois J. Candida vaginitis. Postgrad Med J 1979, 55:645-647.
35. Karaer A., Boylu M., Avsar A.F. Vaginitis in Turkish women: symptoms, epidemiologic - microbiologic association. Eur J Obstet Gynecol Reprod Biol 2005, 121:211-215.
36. Kunzelmann V., Tietz H.J., Rossner D., Czaika V., Hopp M., Schmalreck A., et al. Prerequisites for effective therapy of chronic recurrent vaginal candidiasis. Mycoses 1996, 39:65-72.
37. Liu X.P., Fan S.R. Methylrosaniline chloride stained vaginal smears for the diagnosis of vulvovaginal candidiasis. Int J Gynecol Obstet 2007, 99:83-86.
38. Metts J., Famula T., Trenev N., Clemens R. Lactobacillus acidophilus, strain NAS (H2O2 positive), in reduction of recurrent candidal vulvovaginitis. J Appl Res 2003, 3:340-348.
39. Milanese M., Segat L., De Seta F., Pirulli D., Fabris A., Morgutti M., et al. MBL2 genetic screening in patients with recurrent vaginal infections. Am J Reprod Immunol 2008, 59:146-151.
40. Namkinga L.A., Matee M.I., Kivaisi A.K., Moshiro C. Prevalence and risk factors for vaginal candidiasis among women seeking primary care for genital infections in Dar es Salaam. Tanzania East Afr Med J 2005, 82:138-143.
41. Ohmit S.E., Sobel J.D., Schuman P., Duerr A., Mayer K., Rompalo A., et al. Longitudinal study of mucosal Candida species colonization and candidiasis among human immunodeficiency virus (HIV)-seropositive and at risk HIV-seronegative women. J Infect Dis 2003, 188:118-127.
42. Pappas P.G., Rex J.H., Sobel J.D., Filler S.G., Dismukes W.E., Walsh T.J., et al. Guidelines for treatment of candidiasis. Clin Infect Dis 2004, 38:161-189.
43. Petersen K.A., Matthiesen F., Agger T., Kongerslev L., Thiel S., Cornelissen K., et al. Phase I safety, tolerability, and pharmacokinetic study of recombinant human mannan binding lectin. J Clin Immunol 2006, 26:465-475.
44. Pirotta M., Gunn J., Chondros P., Grover S., O'Malley P., Hurley S., et al. Effect of Lactobacillus in preventing post-antibiotic vulvovaginal candidiasis: a randomised controlled trial. BMJ 2004, 329:548.
45. Pirotta M.V., Garland S.M. Genital Candida species detected in samples from women in Melbourne Australia, before and after treatment with antibiotics. J Clin Microbiol 2006, 44:3213-3217.
46. Powell B.L., Drutz D.J. Confirmation of corticosterone and progesterone binding activity in Candida albicans. J Infect Dis 1983, 147:359.
47. Raylander E., Berglund A.L., Krassny C., Petrini B. Vulvovaginal Candida in a young sexually active population: prevalence and association with oro-genital sex and frequent pain at intercourse. Sex Transm Infect 2004, 80:54-57.
48. Reed B.D., Zazove P., Pierson C.L., Gorenflo D.W., Horrocks J. Candida transmission and sexual behaviors as risks for a repeat episode of Candida vulvovaginitis. J Womens Health 2003, 12:979-989.
49. Reid G., Dols J., Miller W. Targeting the vaginal microbiota with probiotics as a means to counteract infections. Curr Opin Clin Nutr Metab Care 2009, 12:583-587.
50. Richter S.S., Galask R.P., Messer S.A., Hollis R.J., Diekema D.J., Pfaller M.A. Antifungal susceptibilities of Candida species causing vulvovaginitis and epidemiology of recurrent cases. J Clin Microbiol 2005, 43:2155-2162.
51. Ringdahl E.N. Treatment of recurrent vulvovaginal candidiasis. Am Fam Physician 2000, 61:3306-3312.
52. Rylander E., Bergland A.L., Krassny C., Petrini B. Vulvovaginal Candida in a young sexually active population: prevalence and association with oro-genital sex and frequent pain at intercourse. Sex Transm Infect 2004, 80:54-57.
53. Saavedra M., Taylor B., Lukacs N., Fidel P.L. Local production of chemokines during experimental vaginal candidiasis. Infect Immun 1999, 67:5820-5826.
54. Sobel J.D., Chaim W. Vaginal microbiology of women with acute recurrent vulvovaginal candidiasis. J Clin Microbiol 1996, 34:2497-2499.
55. Sobel J.D., Zervos M., Reed B.D., Hooton T., Soper D., Nyirjesy P., et al. Fluconazole susceptibility of vaginal isolates obtained from women with complicated Candida vaginitis: clinical implications. Antimicrob Agents Chemother 2003, 47:34-38.
56. Sobel J.D. Pathogenesis and epidemiology of vulvovaginal candidiasis. Ann N Y Acad Sci 1988, 544: 547-57.
57. Sobel J.D. Pathogenesis and treatment of recurrent vulvovaginal candidiasis. Clin Infect Dis 1992, 14:S148-S153.
58. Sobel J.D. Pathogenesis of Recurrent Vulvovaginal Candidiasis. Curr Infect Dis Rep 2002, 4:514-519.
59. Sobel J.D. Vulvovaginal candidosis. Lancet 2007, 369:1961-1971.
60. Sobel J.D. Vulvovaginitis due to Candida glabrata an emerging problem. Mycoses Probl 1998, 41:18-22.
61. Spaceck J., Buchta V., Jilek P., Förstl M. Clinical aspects and luteal phase assessement in patients with recurrent vulvovaginal candidiasis. Eur J Obstet Gynecol Reprod Biol 2006, 131:198-202.
62. Sullam S.A., Mahfouz A.A., Dabbous N.I., el-Barrawy M., el-Said M.M. Reproductive tract infections among married women in Upper Egypt. East Mediterr Health J 2001, 7:139-146.
63. Tasic S., Tasic N., Tasic A., Mitrovic A. Recurrent genital candidosis of women; consequence of reinfection or relapse. Med Biol 2002, 9:217-222.
64. Taylor B.N., Saavedra M., Fidel P.L. Local Th1/Th2 cytokine production during experimental vaginal candidiasis: potential importance of transforming growth factor-beta. Med Mycol 2000, 38:419-431.
65. Watson C., Calabretto H. Comprehensive review of conventional and non-conventional methods of management of recurrent vulvovaginal candidiasis. Aust N Z J Obstet Gynaecol 2007, 47:262-272.
66. Watson M.C., Grimshaw J.M., Bond C.M., Mollison J., Ludbrook A. Oral versus intra-vaginal imidazole and triazole anti-fungal agents for the treatment of uncomplicated vulvovaginal candidiasis (thrush): a systematic review. BJOG 2002, 109:85-95.
67. White D.J., Vanthuyne A. Vulvovaginal candidiasis. Sex Transm Infect 2006, 82:28-30.
68. Wormley F.L., Chaiban J., Fidel P.L. Cell adhesion molecule and lymphocyte activation marker expression during experimental vaginal candidiasis. Infect Immun 2001, 69:5072-5079.
69. Wormley F.L., Steele C., Wozniak K., Fujihashi K., McGhee J.R., Fidel P.L. Resistance of T-cell receptor delta-chain-deficient mice to experimental Candida albicans vaginitis. Infect Immun 2001, 69:7162-7164.
70. Wozniak K.L., Wormley F.L., Fidel P.L. Candida-specific antibodies during experimental vaginal candidiasis in mice. Infect Immun 2002, 70:5790-5799.